Based on the bioinformatics results, we determined that EMT is an essential gefitinib-resistant mechanism, and TROY modulates CSC properties and gefitinib resistance through EMT in T790M negative NSCLC. The gene discussed is TNFRSF19; the disease is non-small cell lung carcinoma.